Trius therapeutics logo. Trius logo png vectors.

Trius therapeutics logo. Prior to Trius Therapeutics, Mr. About Trius Therapeutics Trius Therapeutics is discovering and developing antibacterial drugs for the treatment of life-threatening infections. Aug 7, 2013 · This work was supported by Trius Therapeutics, Inc. from 2007 until its acquisition by Cubist Pharmaceuticals, Inc. (TSRX) including Market Capitalization, PE Ratio, EBITDA, EPS, previous close and open price, 52 week high & 52 week low, Beta and much more Jun 20, 2023 · 磷酸特地唑胺最早由韩国东亚制药 （Dong-APharmaceutical） 开发，辗转后授权Trius Therapeutics，Cubist制药 （后被默克全资收购） 和拜耳进行商业化开发，在2014年06月20日获得美国FDA批准上市，2015年6月在欧盟上市。 Search Trius Therapeutics Inc business contracts filed with the Securities and Exchange Commission. 17, 2013 /PRNewswire/ -- Auspex Pharmaceuticals, Inc. , or consultants of Trius Therapeutics, Inc. is a biopharmaceutical company focused on the discovery and development of innovative antibiotics for serious infections. Perez, was announced to take leadership on January 1, 2015. Tedizyn is a Trademark by Trius Therapeutics, Inc. 6 billion. Trius Therapeutics (NASDAQ: TSRX) was a biopharma company based in San Diego, CA that focused on the development of antibiotics. Cidara has completed a $32 million Series A financing that will enable it to advance candidates from the company’s Cloudbreak™ targeted immunotherapy platform and CD101 IV (formerly biafungin), a novel long acting echinocandin antifungal drug, into human View Trius Therapeutics Inc contracts and agreements from SEC filings. Previously he was CEO of Trius Therapeutics, Inc. What is Trius Therapeutics? Trius Therapeutics was a biopharma company based in San Diego, CA that focused on the development of antibiotic s. until its sale to Teva Pharmaceutical Industries Ltd. May 5, 2011 · About Trius Therapeutics Trius Therapeutics, Inc. AND BAYER PHARMA AG July 26, 2011 Table of Contents from Trius Therapeutics Inc filed with the Securities and Exchange Commission. Jan 10, 2011 · Trius Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious, life-threatening infections. 00 Oct 16, 2025 · At Tris Pharma, our mission is to uniquely solve some of the most intractable therapeutic challenges in ADHD, pain, addiction and diseases of the central nervous system (CNS). In addition, Trius shareholders will receive a Contingent Value Right that entitles Trius shareholders to receive up to $2. He is also a Board Member of Forge Therapeutics and Speak, Inc. The funds will support the clinical development of torezolid phosphate and general corporate needs. 1 and Amendment No. In addition to the upfront cash payment, each Trius stockholder will receive one Contingent Value Biotech Executive · Accomplished scientist with a track record of building and leading infectious diseases drug discovery teams at Cubist Pharmaceuticals and Trius Therapeutics. . Prior to that, Mr. 4 million in annual revenues, and employs approximately 10 people at this Prior to joining Cidara, Dr. ("CUBIST PHARMACEUTICALS") AND BRGO CORPORATION, A WHOLLY-OWNED SUBSIDIARY OF CUBIST PHARMACEUTICALS ("BRGO" AND TOGETHER WITH CUBIST PHARMACEUTICALS, "CUBIST") AT THE PRICE OF $13. Learn more about Trius Federal Credit Union and why you should become a member of Trius FCU. Mar 13, 2013 · Analyze up to 10 years of full 10K Annual Reports and Quarterly 10Q SEC filings for Trius Therapeutics Inc (TSRX) using our online tools. , a subsidiary of Cubist Pharmaceuticals, Inc. 1, 2013 /PRNewswire/ -- Ryan & Maniskas, LLP is investigating potential claims against the board of directors of Trius Therapeutics, Inc. Trius was acquired by Cubist in 2013. Oct 17, 2013 · Auspex Appoints Pratik Shah as CEO and Expands Executive Team LA JOLLA, Calif. Nov 11, 2010 · Trius Therapeutics, Inc. The current status of the logo is active, which means the logo is currently in use. Mar 10, 2011 · Trius Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious, life-threatening infections. The company's lead product candidate, TR-701 is a oral and IV oxazolidinone antibiotic with potent activity against Gram positive bacterial pathogens. Effective today, Trius common stock will cease to be Trius Download the vector logo of the Trius brand designed by in Encapsulated PostScript (EPS) format. , Oct. The company's lead Feb 27, 2007 · Trius Therapeutics is discovering and developing innovative antibacterial drugs for the treatment of life-threatening infections. company in Company profile page for Trius Therapeutics LLC including stock price, company news, executives, board members, and contact information Jul 31, 2013 · Implications for Trius Shareholders Cubist Pharmaceuticals (CBST) and Trius Therapeutics, Inc. Apr 15, 2010 · Patent application title: METHODS FOR PREPARING OXAZOLIDINONES AND COMPOSITIONS CONTAINING THEM Inventors: Jacqueline A. During his tenure, Trius developed the antibacterial drug tedizolid, which received marketing approval from the U. in Lexington, MA, such as Contacts, Addresses, Reviews, and Registered Agent. Get all financial information for Trius Therapeutics, Inc. Contacts y information about Trius Therapeutics, Inc. "Trius Therapeutics (TSRX) is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious, life-threatening infections. Managerial SEC filings and transcripts for Trius Therapeutics Inc, including financials, news, proxies, indentures, prospectuses, and credit agreements. 2M over 4 rounds from 8 investors. 26 /PRNewswire/ -- Trius Therapeutics, Inc. Yelp is a fun and easy way to find, recommend and talk about what’s great and not so great in San Diego and beyond. S. Duguid (Glenmont, NY, US) Douglas Phillipson (Del Mar, CA, US) Assignees: TRIUS THERAPEUTICS IPC8 Class: AA61K31675FI USPC Class: 514 89 Class name: Phosphorus containing other than solely as part of an Explore the company profile of Trius Therapeutics (triusrx. Aug 9, 2013 · On 08/09/2013 Michael Bemis filed a Corporate - Business court case against Trius Therapeutics Inc in San Diego County Superior Courts. Aug 1, 2013 · Cubist Pharmaceuticals Inc. , Aug. Dec 31, 2003 · 查看医药魔方InvestGO®数据库Trius Therapeutics的公司信息。Trius Therapeutics（Trius Therapeutics Inc. We have successfully completed two Phase 3 clinical trials for Tedizolid Phosphate (TR Who is Trius Therapeutics Trius Therapeutics, Inc. Tedizolid is now marketed by Merck under the name Apr 15, 2011 · In 2010, Trius was awarded a four and one-half year contract with the Defense Threat Reduction Agency, an agency within the Department of Defense for up to $29. This organization primarily operates in the Biological Products, except Diagnostic business / industry within the Chemicals and Allied Products sector. , a pharmaceutical company, following Cubist’s acquisition of Trius. May 4, 2011 · Trius Therapeutics, Inc. (NASDAQ: CBST) and Trius Therapeutics, Inc. Trius Therapeutics is estimated to generate $1. Allergy Laboratories Executives of Trius Therapeutics, Inc Owner, Jeffrey Stein Business classific. Information on acquisition, funding, cap tables, investors, and executives for Trius Therapeutics. We have 5 free Trius logo png, transparent images, vector logos, logo templates and icons. Jul 31, 2013 · Cubist Pharmaceuticals Inc. Trius Therapeutics is carrying out IND-enabling studies for its Gyrase-B development candidate with activity against gram-negative bacterial pathogens including multidrug resistant strains of E Trius Therapeutics (Nasdaq: TSRX) was a biopharma company based in San Diego, CA that focused on the development of antibiotics. Food and Drug Administration in June 2014. 6310 Nancy Ridge Drive Suite 101 San Diego, CA 92121 USATrius Therapeutics focuses on discovery, development, and commercialization of antibiotics and specializes in structure based drug design and has developed antisense technology to identify bacterial drug targets. Maniskas, Esquire) toll-free at (877) 316-3218 or by email at TRIUS THERAPEUTICS in San Diego, reviews by real people. ("TRIUS") AND RECEIVED CONSIDERATION FOR YOUR SHARES IN THE ACQUISITION OF TRIUS BY CUBIST PHARMACEUTICALS, INC. In addition to the upfront cash payment, each stockholder of Optimer will receive a Contingent Value Right (CVR), which is expected Jul 30, 2013 · Cubist Pharmaceuticals, Inc. Including company executives, business partners, clauses and more. There are a number of companies competing in this market and a host of new products in development, but I see tedizolid as Get real-time Trius Therapeutics, Inc. com) featuring business details and insights, funding data, industry info, employee numbers, and more. said Tuesday that it plans to acquire two other drug makers, Optimer and Trius Therapeutics, in an effort to expand its product portfolio. Download free Trius vector logo and icons in AI, EPS, CDR, SVG, PNG formats. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. 50 PER SHARE IN CASH AND ONE CONTINGENT Dr Jeff Stein, President and Chief Executive Officer, Cidara Therapeutics Dr. , a privately-held clinical stage biopharmaceutical company focused on developing innovative therapeutics for the treatment of orphan diseases, today announced the appointment of four life science industry veterans to the company's executive team: Pratik Apr 11, 2011 · Trius Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious, life-threatening infections. Schmid co-founded Trius Therapeutics where he served as the chief financial officer until its merger with Cubist Pharmaceuticals, Inc. The company's lead product candidate, TR-701 is a novel oral and IV oxazolidinone antibiotic with potent activity against Gram positive bacterial pathogens. The company's lead investigational drug, torezolid phosphate, is an IV and orally administered second generation oxazolidinone in Phase 3 clinical development for the treatment of acute bacterial skin and skin Jul 31, 2013 · - Trius Therapeutics: Cubist will acquire all outstanding shares of Trius for $13. The company is addressing the need for novel therapeutics to treat multi-drug-resistant bacterial infections as they become more resistant to currently marketed drugs. 6 billion for Trius Therapeutics Inc and Optimer Pharmaceuticals Inc, expanding its heft in antibiotics at a time when the number of drug Jul 5, 2016 · Previously, Mr. Trius Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. 5 billion. Abdollahian was Vice President of Corporate Development and Mr. Acquired by Cubist Pharmaceuticals. Trius is a San Diego-based biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. The Company’s lead investigational drug, tedizolid phosphate, is a once daily, IV and orally administered second generation oxazolidinone in Phase 3 clinical development for the treatment of serious gram-positive Previously, Mr. Trius' pipeline includes three additional structure-based drug design programs directed against Dec 15, 2011 · In 2020, Forest/AstraZeneca/Dainippon Sumitomo’s Teflaro and Trius Therapeutics’ Tedizolid Will Capture Nearly One-Third o Jun 19, 2023 · Explore Trius Therapeutics, Inc. He also co-founded Trius Therapeutics in 2004, serving as CFO through its IPO and eventual acquisition by Cubist Pharmaceuticals for over $700 million. 50 per share in cash or approximately $707 million on a fully diluted basis. in September 2013. [7] In 2014, succeeding Michael Bonney as President, Robert J. The Company's lead investigational drug, tedizolid phosphate, is a novel antibiotic in Phase 3 clin ical development for the treatment of serious gram-positive infections, including those caused by Aug 1, 2013 · WAYNE, Pa. Trius Therapeutics is a Trademark by Trius Therapeutics, Inc. You can download in PNG, SVG, AI, EPS, CDR formats. , the address on file for this trademark is 6310 Nancy Ridge Drive, Suite 101, San Diego, CA 92121 Jul 30, 2013 · About Trius Therapeutics Trius Therapeutics, Inc. Schmid served as chief financial officer of Auspex Pharmaceuticals, Inc. Use the PitchBook Platform to explore the full profile. 2 to the Schedule 14D-9 previously filed by Trius Therapeutics, Inc. Tedizolid phosphate is a phosphate ester prodrug of the active compound tedizolid. (NASDAQ: CBST) today announced that it has completed the previously announced acquisition of Trius Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious, life-threatening infections. Jun 15, 2025 · Discover Company Info on TRIUS THERAPEUTICS, INC. Jul 30, 2013 · Trius Therapeutics, Inc. Schmid served as Aug 11, 2025 · Discover Company Info on TRIUS THERAPEUTICS, LLC in Boston, MA, such as Contacts, Addresses, Reviews, and Registered Agent. -- (BUSINESS WIRE)--Cubist Pharmaceuticals, Inc. 75 per share in cash, or approximately $535 million on a fully diluted basis. Feb 24, 2011 · Trius Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious, life-threatening infections. (NASDAQ: TSRX) for an aggregate upfront cash consideration of approximately $704 million. Prior to Viking, he was VP of Finance and Chief Accounting Officer at Trius Therapeutics, Inc. 75 million shares and warrants. It was developed by Cubist Pharmaceuticals, following acquisition of Trius Therapeutics (originator: Dong-A Pharmaceuticals), and is marketed for the treatment of acute bacterial skin and skin structure infections Aug 5, 2013 · Cooley LLP announced today that it represented Trius Therapeutics in its acquisition by Cubist Pharmaceuticals. Feb 27, 2007 · SAN DIEGO, Feb. Wondering who provided funding to Trius Therapeutics? InterWest Partners, Prism VentureWorks and Kleiner Perkins Caufield & Byers joined the equity holders in this biopharmaceutical company. 2 of 8 Add your company If your company is not in the database, you can add it by selecting "Add" > "Add Trius Therapeutics () was a biotechnology firm based in San Diego, focusing on the development of antibiotics. Mar 17, 2011 · Trius Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious, life-threatening infections. The deals are valued at $801 million and $818 million, if certain milestones are reached, respectively. (NASDAQ: TSRX) today announced that they have signed a definitive agreement under which Cubist will acquire all outstanding shares of Trius for $13. Trius Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious, life-threatening infections. 5 million. Stein was Chief Executive Officer of Trius Therapeutics from its founding in 2007 until its acquisition by Cubist Pharmaceuticals in September 2013. , the address on file for this trademark is 65 Hayden Avenue, Lexington, MA 02421 Trius Therapeutics Inc ↑ Check whether your company is in the KANDO database by typing its name in the search box 1 of 8 Add your company If your company is not in the database, create an account and, once logged in, add it by selecting "Add" > "Add company" in order to create a profile. Trius Therapeutics (Nasdaq: TSRX) was a biopharma company based in San Diego, CA that focused on the development of antibiotics. During his tenure, Trius developed the antibacterial drug tedizolid, which received About Trius Therapeutics Trius Therapeutics, Inc. IF YOU HELD SHARES OF COMMON STOCK IN TRIUS THERAPEUTICS, INC. All authors are employees and shareholders of Trius Therapeutics, Inc. Federal Vendor Profile for Trius Therapeutics, Inc. May 10, 2011 · Trius Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious, life-threatening infections. Trius Therapeutics (TSRX) is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious, life-threatening infections. Trius was acquired by Cubist in 2013 Trius Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative antibiotics for life-threatening infections. [1] Trius logo png vector transparent. Stein has been President, CEO and Director of Cidara since January 2014. " COLLABORATION AND LICENSEAGREEMENT BETWEEN TRIUS THERAPEUTICS, INC. Aug 1, 2013 · Our investigation concerns possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Trius for not acting in the Company's shareholders' best interests in connection with the sale process. Costello (Troy, NY, US) Robert J. Oct 7, 2025 · Discover Company Info on TRIUS THERAPEUTICS, INC. Mar 23, 2011 · About Trius Therapeutics Trius Therapeutics, Inc. In addition to the upfront cash Trius Therapeutics LLC litigation, intellectual property, attorneys, sec filings, and other public records. Trius Therapeutics is located in Kenilworth, New Jersey. TSRX Stock Company Profile Trius Therapeutics business description, contacts and address | Investors Hangout Tedizolid, sold under the brand name Sivextro (by Merck) is an oxazolidinone -class antibiotic. Onaitis was General Counsel with Trius Therapeutics, where they were key members of the transaction team responsible for the acquisition of Trius by Cubist Pharmaceuticals in 2013. Investors are Sofinnova Ventures, as lead Jun 30, 2014 · Veteran team to apply novel, small molecule immunotherapy platform to treat severe fungal infections in immune compromised patients. (TSRX) announced that they have signed a definitive agreement under which Cubist will acquire all outstanding shares of Trius for $13. Trius logo png vectors. in San Diego, CA, such as Contacts, Addresses, Reviews, and Registered Agent. have signed a merger agreement under which Cubist will acquire all of the outstanding shares of Optimer common stock for $10. The total transaction is valued at up to $818 million. Previously, Mr. [8] In January 2015 Cubist Pharmaceuticals became a wholly owned subsidiary of Merck & Co. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious infections. About Trius Therapeutics Trius Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. In July 2013, Cubist Pharmaceuticals agreed to purchase Trius Therapeutics and Optimer Pharmaceuticals for around $1. and Optimer Pharmaceuticals Inc. (TSRX) stock price, news, financials, community insights, and trading ideas. Raised a total funding of $69. , a Delaware corporation (“Trius” or the “Company”), with the Securities and Exchange Commission on August 13, 2013, August 14, 2013 and August 29, 2013, respectively, relating to the offer by Cubist Jul 31, 2013 · Cubist Pharmaceuticals Inc has agreed to pay up to $1. 3 to Schedule 14D-9 amends and supplements the Schedule 14D-9, Amendment No. Download free Trius vector logo and icons in PNG, SVG, AI, EPS, CDR formats. 50 per share in cash. For more information regarding our investigation, please contact Ryan & Maniskas, LLP (Richard A. [1] Access your Trius Federal Credit Union accounts anywhere you have internet connection and feel safe and secure in doing so - enroll today in our online banking! Trius Winery is a Canadian winemaking pioneer that has been crafting fine VQA wines from premium grapes for over 40 years. Apr 13, 2011 · Trius Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious, life-threatening infections. Michael TRZOSS | Cited by 809 | of Trius Therapeutics, San Diego | Read 17 publications | Contact Michael TRZOSS Oct 26, 2010 · Trius Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious, life-threatening infections. Oct 18, 2025 · Trius Therapeutics - LLC formation guides and services for entrepreneurs across the USA. , the address on file for this trademark is 65 Hayden Avenue, Lexington, MA 02421 Sep 13, 2010 · Trius Reports New Findings on Mechanisms of Antibiotic Resistance in MRSA Data published online ahead of print in Antimicrobial Agents and Chemotherapy and presented Trius Therapeutics is focused on the development of innovative antibiotics for life-threatening infections. Nestled between the Niagara Escarpment and Lake Ontario, we harvest our grapes from four Niagara-on-the-Lake appellations to create distinctive varietals that reflect our region’s unique taste of place. Join 10 million+ investors and traders tracking markets in real-time on Stocktwits. Trius Therapeutics has announced a successful $30 million financing through a private placement, resulting in the issuance of 4. ），公司简介：Trius Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. Simson (Troy, NY, US) Carrie A. concerning possible breaches of fiduciary This Amendment No. Oct 25, 2010 · Trius Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious, life-threatening infections. Schmid was CFO of Auspex Pharmaceuticals, which he took public in 2014 and later sold to Teva for $3. (formerly known as Rx3 Pharmaceuticals), a biopharmaceutical company developing antibacterial drugs for the treatment of serious infections, announced today a $20 million Series A financing. This organization has been operating for approximately 6 years. Trius logo vector. Sep 12, 2013 · Cubist Pharmaceuticals Completes Acquisition of Trius Therapeutics LEXINGTON, Mass. Prior to Trius, he was Director of Lilly Research Labs Finance at Eli Lilly and Company, a pharmaceutical company. Court records for this case are available from San Diego Central Courthouse. with its drug pipeline, therapeutic area, technology platform, 4 clinical trials, 11 news, and 30 literature, Drug:Tedizolid May 30, 2012 · Introduction Trius Therapeutics is in late stage clinical development of its new antibiotic, tedizolid, for treatment of MRSA infections that have increased to epidemic levels in both the hospital and community settings. nfvveomhi 6wsmk6 r2euu 8t6hwe 7k qld xrs xs jtd o2t